[go: up one dir, main page]

NO20062398L - Daily oral controlled release oxycodone dosage form - Google Patents

Daily oral controlled release oxycodone dosage form

Info

Publication number
NO20062398L
NO20062398L NO20062398A NO20062398A NO20062398L NO 20062398 L NO20062398 L NO 20062398L NO 20062398 A NO20062398 A NO 20062398A NO 20062398 A NO20062398 A NO 20062398A NO 20062398 L NO20062398 L NO 20062398L
Authority
NO
Norway
Prior art keywords
profiles
dosage form
controlled release
daily oral
oral controlled
Prior art date
Application number
NO20062398A
Other languages
Norwegian (no)
Inventor
Nishit Modi
Stephen Hwang
Padmaja Shivanand
Original Assignee
Alza Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alza Corp filed Critical Alza Corp
Publication of NO20062398L publication Critical patent/NO20062398L/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)

Abstract

Det er frembragt oksykodonformuleringer som produserer i det vesentlige flate, in vivo tilstandsstabile plasmaprofiler. Toleransenivåer i samband med slike profiler og toleransenivåer i samband med bifasiske profiler er vist å ikke være statistisk ulike. De i det vesentlige flate, in vivo tilstandsstabile plasmaprofiler blir produsert av doseringsformer med i det vesentlige nulte ordens in vitro frigjøringsprofiler. Slike frigjøringsprofiler produserer for lav enkeltdose in vivo Cmaks-nivåer som kan redusere sannsynligheten for skadelige bivirkninger.Oxycodone formulations have been produced which produce substantially flat, in vivo state-stable plasma profiles. Tolerance levels associated with such profiles and tolerance levels associated with biphasic profiles have been shown to be not statistically different. The substantially flat, in vivo state-stable plasma profiles are produced by dosage forms having substantially zero order in vitro release profiles. Such release profiles produce too low single dose in vivo Cmax levels that can reduce the likelihood of adverse side effects.

NO20062398A 2003-10-29 2006-05-26 Daily oral controlled release oxycodone dosage form NO20062398L (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US51588003P 2003-10-29 2003-10-29
PCT/US2004/036132 WO2005041968A2 (en) 2003-10-29 2004-10-28 Once-a-day, oral, controlled-release, oxycodone dosage forms

Publications (1)

Publication Number Publication Date
NO20062398L true NO20062398L (en) 2006-07-27

Family

ID=34549453

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20062398A NO20062398L (en) 2003-10-29 2006-05-26 Daily oral controlled release oxycodone dosage form

Country Status (14)

Country Link
EP (1) EP1677798A2 (en)
JP (1) JP2007509979A (en)
KR (1) KR20060108690A (en)
CN (1) CN1933837A (en)
AU (1) AU2004285547A1 (en)
BR (1) BRPI0415639A (en)
CA (1) CA2546691A1 (en)
EC (1) ECSP066534A (en)
IL (1) IL175193A0 (en)
MA (1) MA28215A1 (en)
NO (1) NO20062398L (en)
RU (1) RU2006118323A (en)
WO (1) WO2005041968A2 (en)
ZA (1) ZA200604310B (en)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20020059653A (en) 1999-10-29 2002-07-13 그린 마틴, 브라이언 쥐 테슬리 Controlled release hydrocodone formulations
US10179130B2 (en) 1999-10-29 2019-01-15 Purdue Pharma L.P. Controlled release hydrocodone formulations
EP2295042A1 (en) 2000-10-30 2011-03-16 Euro-Celtique S.A. Controlled release hydrocodone formulations
UA81224C2 (en) * 2001-05-02 2007-12-25 Euro Celtic S A Dosage form of oxycodone and use thereof
US20110104214A1 (en) 2004-04-15 2011-05-05 Purdue Pharma L.P. Once-a-day oxycodone formulations
US7776314B2 (en) 2002-06-17 2010-08-17 Grunenthal Gmbh Abuse-proofed dosage system
US8075872B2 (en) 2003-08-06 2011-12-13 Gruenenthal Gmbh Abuse-proofed dosage form
DE102005005446A1 (en) 2005-02-04 2006-08-10 Grünenthal GmbH Break-resistant dosage forms with sustained release
DE10361596A1 (en) 2003-12-24 2005-09-29 Grünenthal GmbH Process for producing an anti-abuse dosage form
DE102004032051A1 (en) 2004-07-01 2006-01-19 Grünenthal GmbH Process for the preparation of a secured against misuse, solid dosage form
US20070048228A1 (en) 2003-08-06 2007-03-01 Elisabeth Arkenau-Maric Abuse-proofed dosage form
DE10336400A1 (en) 2003-08-06 2005-03-24 Grünenthal GmbH Anti-abuse dosage form
DE102004032049A1 (en) 2004-07-01 2006-01-19 Grünenthal GmbH Anti-abuse, oral dosage form
DE102005005449A1 (en) 2005-02-04 2006-08-10 Grünenthal GmbH Process for producing an anti-abuse dosage form
SA07280459B1 (en) 2006-08-25 2011-07-20 بيورديو فارما إل. بي. Tamper Resistant Oral Pharmaceutical Dosage Forms Comprising an Opioid Analgesic
DE102007011485A1 (en) 2007-03-07 2008-09-11 Grünenthal GmbH Dosage form with more difficult abuse
MX2010008138A (en) 2008-01-25 2010-08-10 Gruenenthal Gmbh Pharmaceutical dosage form.
US9226907B2 (en) 2008-02-01 2016-01-05 Abbvie Inc. Extended release hydrocodone acetaminophen and related methods and uses thereof
BRPI0912014A2 (en) 2008-05-09 2019-03-06 Grünenthal GmbH A process for preparing an intermediate powder formulation and a final solid dosage form using a spray freeze step
PL2456427T3 (en) 2009-07-22 2015-07-31 Gruenenthal Gmbh Hot-melt extruded controlled release dosage form
RU2015138422A (en) 2009-07-22 2018-12-25 Грюненталь Гмбх STABLE DURING OXIDATION, STRONG-BREAKED DOSAGE FORM
US20110150989A1 (en) * 2009-12-22 2011-06-23 Mallinkckrodt Inc. Methods of Producing Stabilized Solid Dosage Pharmaceutical Compositions Containing Morphinans
US9884022B2 (en) * 2010-04-07 2018-02-06 Lupin Limited Controlled release pharmaceutical compositions of tapentadol
PL2611425T3 (en) 2010-09-02 2014-09-30 Gruenenthal Gmbh Tamper resistant dosage form comprising an anionic polymer
CA2808219C (en) 2010-09-02 2019-05-14 Gruenenthal Gmbh Tamper resistant dosage form comprising inorganic salt
RS56528B1 (en) 2011-07-29 2018-02-28 Gruenenthal Gmbh Tamper-resistant tablet providing immediate drug release
HUE034710T2 (en) 2011-07-29 2018-02-28 Gruenenthal Gmbh Tamper-resistant tablet providing immediate drug release
EP2819656A1 (en) 2012-02-28 2015-01-07 Grünenthal GmbH Tamper-resistant dosage form comprising pharmacologically active compound and anionic polymer
CN104394851B (en) 2012-04-18 2017-12-01 格吕伦塔尔有限公司 Anti-distort and anti-agent amount are come down in torrents pharmaceutical dosage form
US10064945B2 (en) 2012-05-11 2018-09-04 Gruenenthal Gmbh Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc
JP6445537B2 (en) 2013-05-29 2018-12-26 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング Tamper-resistant dosage forms containing one or more particles
WO2014191396A1 (en) 2013-05-29 2014-12-04 Grünenthal GmbH Tamper resistant dosage form with bimodal release profile
KR20160031526A (en) 2013-07-12 2016-03-22 그뤼넨탈 게엠베하 Tamper-resistant dosage form containing ethylene-vinyl acetate polymer
WO2015078891A1 (en) 2013-11-26 2015-06-04 Farmaceutici Formenti S.P.A. Preparation of a powdery pharmaceutical composition by means of cryo-milling
CN106572980A (en) 2014-05-12 2017-04-19 格吕伦塔尔有限公司 Tamper resistant immediate release capsule formulation comprising tapentadol
AU2015266117A1 (en) 2014-05-26 2016-11-24 Grunenthal Gmbh Multiparticles safeguarded against ethanolic dose-dumping
JP2018517676A (en) 2015-04-24 2018-07-05 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング Anti-modification formulation with immediate release and resistance to solvent extraction
JP2018526414A (en) 2015-09-10 2018-09-13 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング Protection against oral overdose with abuse-inhibiting immediate release formulations
US11337977B2 (en) 2016-08-10 2022-05-24 Genentech, Inc. Pharmaceutical compositions comprising Akt protein kinase inhibitors

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5914131A (en) * 1994-07-07 1999-06-22 Alza Corporation Hydromorphone therapy
UA81224C2 (en) * 2001-05-02 2007-12-25 Euro Celtic S A Dosage form of oxycodone and use thereof
US20040010000A1 (en) * 2002-04-29 2004-01-15 Ayer Atul D. Methods and dosage forms for controlled delivery of oxycodone
MXPA04012021A (en) * 2002-05-31 2005-08-16 Johnson & Johnson Dosage forms and compositions for osmotic delivery of variable dosages of oxycodone.

Also Published As

Publication number Publication date
CA2546691A1 (en) 2005-05-12
AU2004285547A1 (en) 2005-05-12
JP2007509979A (en) 2007-04-19
WO2005041968A3 (en) 2006-06-22
WO2005041968A2 (en) 2005-05-12
MA28215A1 (en) 2006-10-02
EP1677798A2 (en) 2006-07-12
BRPI0415639A (en) 2006-12-12
ZA200604310B (en) 2007-11-28
RU2006118323A (en) 2007-12-10
KR20060108690A (en) 2006-10-18
CN1933837A (en) 2007-03-21
IL175193A0 (en) 2008-04-13
ECSP066534A (en) 2006-11-24

Similar Documents

Publication Publication Date Title
NO20062398L (en) Daily oral controlled release oxycodone dosage form
TW200718689A (en) 2-Amino-quinazolin-5-ones
CY1112478T1 (en) KINAZOLINONE COMPOUNDS AS ANTI-CANCER FACTORS
GEP20125701B (en) Application of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2h-pyrimidin-1-ylmethyl]-4-fluoro-benzonitrile
MXPA05013142A (en) Pyridino[1,2-a]pyrimidin-4-one compounds as anticancer agents.
NO20076613L (en) Pharmaceutical Formulations and Their Use
WO2005070930A3 (en) Tetrahydrocarboline compounds as anticancer agents
SG166093A1 (en) Inhibitors of brutonæs tyrosine kinase
MY147393A (en) Administration of dipeptidyl peptidase inhibitors
TW200630093A (en) Dose forms
MY143604A (en) 2-amino-7,8-dihydro-6h-pyrido [4,3-d] pyrimidin-5-ones
EG25822A (en) Quinolinyl-pyrrolopyrazoles
TW200716628A (en) Novel compounds
WO2006060507A3 (en) Compositions comprising immunomodulatory compounds and the use thereof for the treatment of immunodeficiency disorders
NZ588913A (en) Liver cancer drug
WO2004006859A3 (en) Platinum compound
TNSN07263A1 (en) Substituted 4-phenyl tetrahydroisoquinolines, methods for producing them, their use as drug, and drug containing them
MY133107A (en) Use of pyrimidine derivatives for the prophylaxis and therapy of cerebral ischemia
EP1503748A4 (en) Drugs for mitigating taxane-induced neurotoxicity
RU2007122391A (en) S-MIRTAZAPINE FOR TIDAL TREATMENT
MX2010005009A (en) Use of immunomodulatory compounds for the treatment of disorders associated with endothelial dysfunction.
EA200801890A1 (en) MEANS FOR THE TREATMENT OF NOISE IN THE EARS
PT1718651E (en) 7h-pyrrolopyrimidine derivatives
TW200616951A (en) Indole derivatives, their manufacture and use as pharmaceutial agents
UA93689C2 (en) Administration of dipeptidyl peptidase inhibitors

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application